Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 17INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Melanoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Thymalfasin × Clear all
NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00911443 2009-07-09

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

sigma-tau i.f.r. S.p.A.

Phase 2 Completed
488 enrolled 12 charts
Dermatologic

Melanoma

NCT00082082 2008-01-15

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

SciClone Pharmaceuticals

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡